MarketPeel
Insider Trading Intelligence
DC

David Alan Campbell

JANX
PRESIDENT AND CEO · JANUX THERAPEUTICS, INC. · CIK 0001864158
FILING MIX · LIFETIME39%/61%
BUYS
7
SELLS
11
TOTAL VALUE
$6.61M
COMPANIES
1
ACTIVE SINCE
Jan 2022
HOLDINGS NOW
284,982
AVG SELL PX
$51.59
TRADE KIND
SHOWING 18 / 18
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
11 backtested trades · 8 horizons · 12 pending
Forward-return performance of every backtestable P/S trade by David Alan Campbell, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d11+63.64%-5.10%-0.29%-4.81%-2.92%
14d11+36.36%+4.14%+1.32%+2.83%+5.08%
30d11+45.45%-0.50%+1.49%-1.99%+0.70%
60d11+72.73%-10.97%+2.02%-12.99%-3.26%
90d11+63.64%-16.71%-0.08%-16.62%-23.44%
180d11+90.91%-40.96%+0.02%-40.98%-38.29%
1y11(1 pending)+100.00%-51.92%+16.17%-68.10%-66.32%
2y11(11 pending)
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
JANX · 284,982 shares · as of Jan 2, 2026
095,396190,791286,187381,5822023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
FLOW · 7 buys / 11 sellsCOVERAGE · 17 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
JANX
JANUX THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
96,600381,582Jan 2, 2026Jan 2, 2025View →
JANX
JANUX THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
338,100338,100Jan 2, 2026Jan 2, 2025View →
JANX
JANUX THERAPEUTICS, INC.
SALE
President and CEO
8,072$13.73$110.8K284,982Jan 2, 2026Jan 2, 2025View →
JANX
JANUX THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
5,000$60.00$300.0K293,054Jan 7, 2025Jan 8, 2025View →
JANX
JANUX THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
283,500283,500Jan 2, 2025Jan 3, 2025View →
JANX
JANUX THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
81,000298,054Jan 2, 2025Jan 3, 2025View →
JANX
JANUX THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
25,000$56.19$1.40M217,054Dec 24, 2024Dec 27, 2024View →
JANX
JANUX THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
15,000$67.00$1.00M242,054Dec 3, 2024Dec 3, 2024View →
JANX
JANUX THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
18,281$51.43$940.2K263,773Nov 25, 2024Nov 27, 2024View →
JANX
JANUX THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
6,719$52.04$349.6K257,054Nov 25, 2024Nov 27, 2024View →
JANX
JANUX THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
11,103$53.94$598.9K282,054Oct 28, 2024Oct 30, 2024View →
JANX
JANUX THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
13,897$53.22$739.6K293,157Oct 28, 2024Oct 30, 2024View →
JANX
JANUX THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
18,957$46.09$873.7K313,097Sep 27, 2024Sep 27, 2024View →
JANX
JANUX THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
5,248$46.86$245.9K307,849Sep 27, 2024Sep 27, 2024View →
JANX
JANUX THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
795$47.84$38.0K307,054Sep 27, 2024Sep 27, 2024View →
JANX
JANUX THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
356,500356,500Jan 2, 2024Jan 3, 2024View →
JANX
JANUX THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
310,000310,000Jan 3, 2023Jan 5, 2023View →
JANX
JANUX THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
354,250354,250Jan 3, 2022Jan 5, 2022View →
Other insiders · JANX
Loading peer insiders…
About this filer
CIK 0001864158
ROLE
President and CEO
PRIMARY
JANX
COMPANIES
1
ACTIVE SINCE
Jan 2022
MARKETPEEL · /INSIDER/0001864158DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback